Market Analysis - Unibest Industrial Co., Ltd.

Blogs

Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Lenacapavir: Market Analysis of the First-in-Class Capsid Inhibitor
2023-10-13

In August 2022, Gilead announced that the European Commission (EC) has granted marketing authorization for Sunlenca (Lenacapavir), an innovative treatment for adults with multi-drug resistant HIV infection. The treatment works in combination with other antiretroviral(s) when it isn't Read More
A Breif Drug Development Analysis of Antiretrovirals
2023-09-26

Antiretroviral drugs have evolved significantly over time, with new drugs continuously being developed. The analysis below provides some insights into the development timeline, the focus on drug classes, and the use of drugs in combination formulations.Evolution of Drug ClassesThe following timeline Read More
Trilaciclib, The First-in-Class Myeoprotection: Market, Advantages, and Competitions
2023-09-15

In recent years, the concept of myeloprotection—protecting bone marrow from the damaging effects of chemotherapy—has emerged as a crucial component in cancer therapy. In the face of this evolving landscape, G1 Therapeutics' trilaciclib (marketed as COSELA®) stands out. Trilaciclib is the first thera Read More
Pralsetinib and NSCLC
2023-09-14

Compounds with CAS RN 2097133-17-8, CAS RN 2778223-52-0 and CAS RN 35277-02-2 can be used to synthesize Read More